文献速递乳腺癌支持与姑息治疗

250例接受乳腺癌化疗的育龄女性血清抗苗勒管激素动态变化的前瞻性评估

Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
PubMed 文献 · Eur J Cancer · 2017-04-29

这项前瞻性队列研究纳入250例18-39岁接受辅助或新辅助化疗的乳腺癌患者,在每个化疗周期及化疗后6、12、24个月检测血清抗苗勒管激素(AMH)并记录月经情况。结果显示AMH在每个化疗周期后快速下降至多数患者不可测水平,45%的患者在24个月随访期间缓慢回升;化疗结束时化疗相关闭经发生率为92.4%。

要点

  • 化疗后AMH快速降至多数患者不可测水平,45%的患者24个月内缓慢回升。
  • 化疗结束时化疗相关闭经发生率为92.4%,闭经者年龄更大、基线AMH更低。
  • AMH下降与年龄和基线AMH显著相关,与环磷酰胺剂量和他莫昔芬使用无关。

核心结论

  • 研究证实接受乳腺癌化疗的年轻女性卵巢储备快速且深度受损,部分患者AMH出现中度恢复。
  • 作者认为AMH不能单独预测生育潜力,但强调治疗后卵巢功能不全随访的必要性,强烈支持采用生育力保存策略,并可能为改善咨询提供新工具。

研究设计与样本

  • 前瞻性队列研究,纳入250例18-39岁确诊乳腺癌并接受辅助或新辅助化疗的患者。
  • 每个化疗周期及化疗后6、12、24个月检测血清AMH,并记录月经来潮情况。

主要发现

  • 平均基线AMH水平为4.19 ± 4.84 ng/mL,与年龄呈负相关。
  • 所有患者在每个化疗周期后血清AMH快速下降,多数降至不可测水平;45%的患者在24个月随访期间AMH缓慢升高。
  • AMH下降与年龄和基线AMH水平显著相关,与环磷酰胺剂量和他莫昔芬使用无关。
  • 化疗结束时化疗相关闭经发生率为92.4%;闭经女性较恢复月经者年龄显著更大、基线AMH更低。

临床怎么用

  • 作者认为AMH不能单独预测生育潜力,强调治疗后需随访卵巢功能不全,并强烈支持采用生育力保存策略,可能为改善咨询提供新工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little is known on ovarian damage during chemotherapy and its evolution during long-term follow-up. The aim of this study was to provide a detailed description of serum anti-Müllerian hormone (AMH) evolution during chemotherapy and 24-month follow-up. METHODS: This prospective cohort study was conducted in 250 patients, aged 18-39 years, diagnosed with breast cancer and treated with adjuvant/neoadjuvant chemotherapy. Each patient underwent blood AMH measurement at each chemotherapy cycle, and at 6, 12 and 24 months after chemotherapy. Menses occurrence was also recorded. RESULTS: Mean basal AMH level was 4.19 ± 4.84 ng/mL, and was negatively correlated with age. Serum AMH level rapidly decreased in all patients after each chemotherapy cycle to undetectable levels in most of them, and slowly increased in 45% of the patients during the 24-month follow-up. AMH decrease was significantly associated with age and basal AMH level, but not with cyclophosphamide dose and tamoxifen use. The prevalence of chemotherapy-related amenorrhoea was 92.4% at the end of chemotherapy; women with amenorrhoea being significantly older and having lower basal AMH than women who resumed menses. CONCLUSIONS: Our study confirms rapid and deep ovarian reserve alteration in young women receiving chemotherapy for breast cancer, and shows moderate AMH recovery in some patients. Although AMH cannot alone predict fertility potential, these new data emphasise the need for post-treatment ovarian insufficiency follow-up, strongly support the use of fertility preservation strategies and may provide new tools for improved counselling.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dezellus A, Barriere P, Campone M, et al. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017. PMID: 28463758. doi:10.1016/j.ejca.2017.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。